Company Profile

Senseonics Stock Price, News & Catalysts

Ticker:
SENS
Exchange:
NYSE
Sector:
Biopharma
Location:
United States

Stock performance

8.90 USD (-8.57%)

Close

Last updated: November 19, 2026

359M USD

Market cap

Why the stock is moving

As of Nov 19, 2026, SENS closed down 8.57% at $8.90. No new same-company headline was identified in the current news window.

Company overview

Implantable Glucose Monitoring

Senseonics develops long-term implantable continuous glucose-monitoring systems for people with diabetes. Its fluorescence-based sensor is placed under the skin rather than replaced every one to two weeks like conventional transcutaneous sensors.

Eversense 365

Eversense 365 is designed to provide up to one year of continuous glucose data from a single implanted sensor. A removable and rechargeable smart transmitter powers the sensor and sends readings and alerts to a mobile application.

Commercial Model

Senseonics manufactures the Eversense system and directly manages U.S. commercialization. The company is expanding a network of trained inserters while also bringing more international commercial activity in-house.

Connected Diabetes Ecosystem

The company is integrating Eversense 365 with automated insulin-delivery systems, beginning with the iLet Bionic Pancreas. It is also advancing Freedom, a next-generation implantable CGM designed to communicate directly with a mobile device without an on-body component.

Future catalysts

  • Commercial launch of Eversense 365 integration with the iLet Bionic Pancreas in the fourth quarter of 2026, subject to completion of integration work and applicable requirements.

Recent news

  1. 01
  2. 02
  3. 03
  4. 04
  5. 05

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

Frequently Asked Questions

What is the current stock price of Senseonics (SENS)?

Senseonics (SENS) most recently closed at 8.90 USD, a -8.57% move versus the previous session.

What is the market cap of Senseonics (SENS)?

Senseonics currently has a market capitalization of 359M USD on BioPharmSignal.

What does Senseonics do?

Implantable Glucose Monitoring Senseonics develops long-term implantable continuous glucose-monitoring systems for people with diabetes. Its fluorescence-based sensor is placed under the skin rather than replaced every one to two weeks like conventional transcutaneous sensors. Eversense 365 Eversense 365 is designed to provide up to one year of continuous...

On which exchange is SENS stock listed?

Senseonics (SENS) is associated with NYSE, United States, Biopharma.

What is Implantable?

Implantable Glucose Monitoring Senseonics develops long-term implantable continuous glucose-monitoring systems for people with diabetes.

Which conditions is Senseonics targeting with Implantable?

Senseonics is associated with diabetes based on its company overview and current catalyst commentary.

How does Senseonics describe recent progress with Implantable?

Commercial launch of Eversense 365 integration with the iLet Bionic Pancreas in the fourth quarter of 2026, subject to completion of integration work and applicable requirements.

What is Glucose?

Implantable Glucose Monitoring Senseonics develops long-term implantable continuous glucose-monitoring systems for people with diabetes.